Trial
NCT04601077
The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African American and Hispanic Origin
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Nitric Oxide Innovations LLC
Collaborators
—
Condition
COVID-19
Intervention
Nitric Oxide lozenges, 30 mg
Why stopped
The study stopped due to futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-06